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1. Introduction 
Genital human papillomavirus (HPV) infection is a most common sexually transmitted 
infection among women (Muñoz et al., 2003). The immune system effectively repels most 
HPV infections, and is associated with strong localized cell mediated immune responses. 
However, approximately ten percent of individuals develop a persistent infection, with risk 
of development of high-grade precursor lesions and eventually invasive carcinoma (Stanley, 
2006). The causal role of HPV in all cancers of the uterine cervix has been firmly established 
(zur Hausen, 1999; Walboomers et al., 1999; Bosch et al., 2008). Most cancers of the vulva 
and vagina are also induced by oncogenic HPV types. In precancerous lesions, most HPV 
genomes persist in an episomal state whereas, in many high-grade lesions and carcinomas, 
genomes are found integrated into the host chromosome. Two viral genes, E6 and E7, are 
invariably expressed in HPV-positive cancer cells. Their gene products are known to 
inactivate the major tumour suppressors, p53 and retinoblastoma protein (pRB), 
respectively. In addition, E6 oncoprotein is also capable to up regulate the expression of 
inhibitors of apoptosis, and E6 and E7 cooperate to effectively immortalise primary 
epithelial cells. Tumour formation is not an inevitable consequence of viral infection; it 
rather reflects the multi-step nature of oncogenesis where each step constitutes an 
independent (reversible or irreversible) genetic change that cumulatively contributes to 
deregulation of cell cycle, cell growth and survival. 
2. Human papillomaviruses 
Human papillomaviruses are a large family of small double-stranded DNA viruses which 
infect squamous epithelia (or cells with the potential for squamous maturation). 
Papillomaviruses are classified by genotype, and at present, about 130 types have been 
identified by sequences of the gene encoding the major capsid protein L1 (de Villiers et al.; 
2004; Bravo et al., 2010, Van Doorslaer el al., 2011). HPVs can be classified into high or low-
risk types depending upon their oncogenic potential. High-risk genotypes 16 and 18 are 
associated with 70% of cervical carcinoma (Muñoz et al., 2006), and about 80% HPV positive 
vulval and vaginal carcinoma (Madeleine et al., 1997; Daling et al., 2002; Hampl et al., 2006). 
Low-risk types 6 and 11 have been isolated in 90% of genital warts (Aubin et al., 2008). 
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2.1 HPV genome organization 
Virus particles consist of about 7900 base-pairs (7.9 kbp) long circular DNA molecules 
wrapped into a protein shell. The HPV genome can be functionally divided into two 
regions: Upstream Regulatory Region (URR) and Open Reading Frames (ORFs). URR does 
not code for proteins but contains cis-elements required for the regulation of the gene 
expression, replication of the genome, and its packaging into virus particles. ORFs can be 
divided into the Early Region (E), necessary for the replication, cellular transformation and 
the control of viral transcription, and Late Region (L) that codes for the capsid proteins that 
comprises the outer coat of the virus (Figure 1). 
 
 
Fig. 1. Schematic presentation of the HPV genome. The non-coding region is the upstream 
regulatory region (URR). The open reading frames (ORFs) encode the early (E), and late (L) 
viral proteins. (Adapted from Muñoz et al., 2006). 
Within the Early Regions (E) it is possible to distinguish different genes with specific 
functions. E1 and E2 genes have an important role in basal DNA replication. During viral 
persistence, the immune system keeps the infection in this state. E2 participates in the 
regulation of LCR (low-copy repeats) transcriptions, and decreases the expression of E6 and 
E7. The E4 gene codes for one family of small proteins involved in the transformation of the 
host cell by producing alterations of the mitotic signals and interacting with keratin. E5 
decreases intercellular communication and isolates the transformed cells and interacts with 
the growth factor's receptors and encourages cellular proliferation. It also stimulates the 
expression of E6 and E7. E6 is oncogenic, stimulating the growth and transformation of the 
host cell by the inhibition of protein p53's normal tumour-suppressor function. E7 also acts 
as an oncogene, inducing cellular proliferation by inhibition of protein pRb. Within the Late 
Region (L), it is possible to distinguish the L1 gene, which codes for the major capsid protein 
and can form virus-like particles and L2, which codes for the minor capsid protein (Jones & 
Wells, 2006).  
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2.2 Natural history of genital HPV infection 
Genital HPV infections are a very common sexually transmitted infection among women 
with a lifetime risk of 50-80% and have a peak prevalence between ages 18 and 30 (Koutsky, 
1997). Most of these infections clear spontaneously. Seventy five per cent of infections clear 
within a year, and individuals with suboptimal immune responses may be at increased risk 
of persistent HPV infection and associated malignancy (Stanley, 2006). At present, in the 
female genital tract about 40 genotypes of HPV can be isolated; nevertheless only 15 types 
are usually associated with development of carcinoma. Genotypes 16 and 18 have been 
clearly shown to be predominant carcinogenic human viral agents, but in the majority of 
cases the presence of HPV alone is not sufficient for the development of neoplasm and 
different cofactors have been identified: tobacco, other sexually transmitted diseases (e.g. 
HIV), conditions of temporary immunodeficiency, alterations of hormonal status, beta-
carotene deficiency, repeated local traumas, promiscuity and some modalities of sexual 
behaviour (Au, 2005; Cotton et al., 2007).  
2.3 HPV life cycle 
HPVs are perfectly adapted to their natural host tissue, the differentiating epithelial cells of 
skin or mucosa and exploit the cellular machinery for their own purposes. HPVs are 
undergoing a complete life cycle only in fully differentiated squamous epithelium. These 
viruses infect the basal cell layer where they establish their small double-stranded DNA 
genome, as a circular extra-chromosomal element or episome in the nucleus of infected cells. 
Following the entry into the suprabasal layer, the viral genome replicates and in the upper 
layers of epidermis complete viral particles are released (Doorbar, 2005). Existence of the viral 
genome in the infected cell is central to the life cycle of papillomaviruses and their associated 
pathologies. Maintenance of the viral genome requires the activity of E1 (the replicative 
helicase of papillomavirus) and E2, the two viral proteins necessary for replication of the HPV 
genome in conjunction with the host cell DNA replication machinery. As an initiator protein 
E1 acts both as a DNA binding protein to recognize the viral origin of DNA replication and 
subsequently as a helicase to unwind the origin and the DNA ahead of the replication fork. In 
lesions containing HPV episomes, the viral E2 protein directly represses early gene expression 
as part of a mechanism to regulate copy number. Integration of viral DNA usually disrupts E2 
expression, leading to the deregulated expression of early viral genes, including E6 and E7. 
The expression of viral gene products is closely regulated as the infected basal cell migrates 
towards the epithelial surface. Genome amplification, which is necessary for the production of 
infectious virions, is prevented until the levels of viral replication proteins rise, and depends 
on the co-expression of several viral proteins. Viral persistence leads to clonal progression of 
the persistently infected epithelium. Events which are still not completely understood lead 
infected cells to malignant transformation. Tumour formation is not an inevitable consequence 
of viral infection; it rather reflects the multi-step nature of oncogenesis where each step 
constitutes an independent (reversible or irreversible) genetic change that cumulatively 
contributes to deregulation of cell cycle, cell growth and survival (Bosch et al., 2008). 
3. HPV DNA replication 
The papillomaviruses DNA replication is totally dependent upon the cellular DNA synthesis 
machinery. The problem for the virus is that the necessary cellular DNA polymerases and 
replication factors are only available in dividing cells. However, the virus replicates in non-
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dividing cells. To solve this problem, HPV encodes proteins that, in the context of the viral life 
cycle, reactivate cellular DNA synthesis in non-cycling cells, inhibit apoptosis, and delay the 
differentiation program of the infected keratinocyte, creating an environment permissive for 
viral DNA replication (Münger & Howley, 2002). The precise details by which this is achieved 
are not completely understood, but the relevant viral genes are E6 and E7. Rarely, by-product 
of high-risk HPV replication is the deregulation of growth control in the infected cell and the 
development of cancer (Swan et al., 1994; zur Hausen, 2002). The HPV episome is replicated by 
the viral E1 and E2 proteins together with the host DNA replication machinery. E1 acts both as 
a DNA binding protein to recognize the viral origin and subsequently as a helicase to unwind 
the DNA ahead of the replication. Structure-function studies have indicated that E1 is a 
modular protein comprised of a C-terminal enzymatic domain with ATPase/helicase activity, 
a replication origin DNA-binding domain located in the centre of the protein and the N-
terminal regulatory domain. E1 binds to DNA with little sequence specificity. In vitro and in 
vivo, binding of E1 specifically to the origin is facilitated by its interaction with E2, a 
transcription/replication factor that binds with high affinity to sites in the viral origin. 
Assembly of a ternary complex between E1, E2 and the origin serves as a starting point for the 
assembly of a larger E1 complex that has unwinding activity, most likely a double hexamer 
necessary for bidirectional unwinding. E1 interacts with DNA replication factors, including the 
polymerase α-primase and the single-stranded binding protein RPA (Replication Protein A), to 
promote viral DNA replication (Thierry et al., 2004). 
3.1 Inhibitors of HPV DNA replication 
Interaction between the E2 protein and E1 helicase of human papillomaviruses is essential 
for the initiation of viral DNA replication. Research performed by Wang and colleagues 
(2004) led to the identification of the first small molecule inhibitors of HPV DNA replication. 
Characterization of their mechanism of action showed that this class of inhibitors binds to 
E2 and prevents its interaction with the E1 helicase. These inhibitors defined a previously 
unrecognized small-molecule binding pocket on E2. This class of inhibitors was found to 
antagonize specifically the E1-E2 interaction in vivo and to inhibit HPV DNA replication in 
transiently infected cells. These results highlighted for the first time the potential of the E1-
E2 interaction as a small molecule antiviral target for the treatment of HPV infections (White 
et al., 2011). These inhibitors also provided a rare example of a class of small molecules that 
can antagonize a protein-protein interaction. 
4. HPV-induced oncogenesis 
The female genital tract, a continuum of squamous epithelium from the vulva to the cervix, 
is commonly infected by human papillomavirus. The outcome of HPV infection depends on 
the immune response, the viral genotype (low-risk or high-risk/oncogenic) and the site of 
infection (the cervical squamo-columnar junction is more susceptible to HPV disease). The 
key role of HPV in most cancers of the female lower genital tract has been firmly established 
biologically and epidemiologically (Herrero et al., 2000; Daling et al., 2002; Böhmer et al., 
2003; Moscicki et al., 2006).  
4.1 Malignant transformation of the lower genital tract 
The cervical cancer is marked by a premalignant phase of various grades of cervical 
intraepithelial neoplasm (CIN) which is a genetically unstable lesion and is characterized by 
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a spectrum of histological abnormalities. HPV viral integration into the host genomic DNA 
is associated with progressive genetic instability, and these events play a fundamental role 
in the progression from low-grade (CIN1) to high-grade (CIN2/3) lesions, and eventually to 
invasive cervical cancer (ICC). In longitudinal natural history studies, the time from the 
detection of high-risk HPV to the development of CIN3 is 3–5 years (Herrero et al., 2000), 
but the progression to ICC takes a further 10–20 years (Moscicki et al., 2006), and probably 
only 30–40% of CIN3 actually progress to invasive carcinoma (McCredie et al., 2008). Most 
cancers of the vulva and vagina in younger women are also induced by oncogenic HPV 
types (Madeleine et al., 1997; Hampl et al., 2006). These cancers are preceded by high-grade 
vulval intraepithelial neoplasia (VIN2/3) and vaginal intraepithelial neoplasia (VaIN2/3). 
Compared with cervical cancer, vulval and vaginal cancers develop less frequently. 
4.2 Molecular basis of HPV-induced oncogenesis 
The HPV DNA usually exists as extrachromosomal plasmid, mostly as a monomeric circular 
molecule in benign cervical precursor lesions. However, in cervical cancer cells the HPV 
DNA is integrated in the host genome. During HPV DNA integration, the viral genome 
breaks in the E1/E2 region. The break leads to the loss of the E2, which encodes proteins 
including one that inhibits the transcription of the E6 and E7 regions, resulting in increased 
expression of E6 and E7 oncogenic proteins (Moon et al., 2001). The proteins coded by these 
genes are multifunctional and interfere with important cell cycle regulatory proteins. 
Expression of viral oncogenes is tightly controlled in non-differentiated keratinocytes by at 
least two signalling cascades, one operative at the functional level and the other at the 
transcriptional level. Integration of the viral DNA could occur, resulting in increased 
expression of E6 and E7. Additionally, mutations or methylation of host DNA could occur 
that abrogate the transcriptional control of differentiation and viral gene expression; there is 
evidence for both of these mechanisms (Pett & Coleman, 2007; Kalantari et al., 2004). The 
oncoproteins E6 and E7 interact with many cellular proteins and change fundamental 
cellular functions like cell cycle regulation, telomere maintenance, susceptibility to 
apoptosis, intercellular adhesion and regulation of the immune response. These effects are 
in accordance with the essential changes in cell physiology that are acquired during tumour 
development and that have been proposed by Hanahan & Weinberg (2000). Evading the 
immune system surveillance has been recognized as an additional basic feature of malignant 
growth (Katz et al., 2008). 
4.3 Regulation of the cell cycle 
Maintenance of genetic integrity from one generation to the next requires the accurate 
replication of chromosomes during the S-phase and their faithful segregation during 
mitosis. The protein p53 (Figure 2) is know as the “genome’s guardian” (Lane, 1992) and in 
the case of DNA damage, p53 can provoke the arrest of cellular division to assure the time 
necessary for DNA repair. 
If damage can not be repaired, p53 is able to induce the programmed cellular death 
(apoptosis) and prevent the propagation of DNA damage in the subsequent generation of 
cells. The product of another tumour suppressor gene, pRb acts as a repressor of E2F 
transcription factor (Wu et al., 2000). E2F regulates various genes including those involved 
in the progression of the cell cycle (the G1-S transition). By binding E2F, pRb prevents the 
entry into the S phase, providing the time for checking genome integrity (Figure 3). 
Oncoproteins E6 and E7 cooperatively disrupt the functions of p53 and pRb, with profound 
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changes in the cell cycle regulation (Vousden, 1993; Tungteakkhun & Duerksen-Hughes, 
2008). Furthermore, E6 and E7 proteins can provoke directly DNA mutations of the host cell 
(Havre et al., 1995; Reznikoff et al., 1996; Moody & Laimins, 2010). As an aberration of virus 
infection, constant activity of the viral proteins E6 and E7 leads to increasing genomic 
instability, accumulation of gene mutations, further loss of cell-growth control and 
ultimately cancer (Münger et al., 1992; Ishiji, 2000). 
 
 
 
 
Fig. 2. Structural features of the p53 tumour suppressor gene. The transcription activation 
site (TAS), heat shock protein binding site (HSP), SV40 large T-antigen binding sites (SV40), 
adenovirus E1b and papillomavirus E6 binding sites, cellular Mdm2 binding site, nuclear 
localization signal (NLS), oligomerization domain (OLIGO) and phosphorylation sites (cdc2  
and CDK) are indicated. The five evolutionarily conserved domains are labeled HCD I - V 
and the hot spot regions are HSR A-D (Adapted from Mietz et al., 1992). 
 
 
 
 
Fig. 3. Regulation of cell cycle: the role of p53 and pRb 
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4.3.1 Oncoprotein E6 functions 
HPV 16 E6 is a 151 amino acid protein with two zinc finger domains. E6 is one of the 
primary oncogenes of the virus (Rapp & Chen, 1998; Fan & Chen, 2004). E6 together with E7 
causes immortalization of cells and plays important roles in malignant transformation. 
Oncoprotein E6 interacts with numerous cellular proteins (Table 1).  
 
Oncoprotein E6 functions Investigators, year 
Cell immortalization Band et al., 1990 
Binding of E6-AP results in degradation of p53 Tommasino et al., 2003 
Antiapoptic effect Thomas & Banks, 1998 
Chromosomal destabilization White et al., 1994 
Foreign DNA integration Kessis et al., 1996 
Enhancement of DNA mutagenicity Havre et al., 1995 
Activation of telomerase Klingelhutz et al., 1996 
Blockade of interferon Ronco et al., 1998 
E2F-regulated mitotic genes Thierry et al., 2004 
E6 I/E6 II gene expression Moodley et al., 2003 
Table 1. Identified functions of the high-risk HPV oncoprotein E6  
E6 targets p53 through recruitment of a cellular E3 ubiquitin ligase - E6 associated protein 
(E6AP). This trimeric complex leads to p53 degradation by ubiquitin-proteosomal pathway. 
Besides targeting it for degradation, E6 is capable of binding directly to p53, interfering with 
its DNA-binding activity (Lechner & Laimins, 1994). In addition, E6 protein blocks 
apoptosis, alters the transcription machinery and disturbs intercellular interactions, a crucial 
step towards malignancy. Another important target for E6 is the group of PDZ proteins 
(Wise-Draper & Wells, 2008). The name is related to the first three members identified: PSD-
95 (a post-synaptic density signalling protein), Dlg (the Drosophila disc large protein) and 
ZO1 (the zonula occludens 1 protein with functional roles in epithelial polarity). Only high-
risk E6 associates with PDZ proteins. These proteins play important role in cell signalling, 
cell adhesion and tight-junction integrity (Fanning & Anderson, 1999). Experimental 
evidence indicates that the interaction of E6 with PDZ proteins is necessary for development 
of epithelial hyperplasia (Nguyen, 2003).  
4.3.2 Oncoprotein E7 functions  
HPV 16 E7, a nuclear protein of 98 amino acids, has a casein kinase II phosphorylation site at 
serine residues 31 and 32 (Firzlaff et al., 1991). E7 interacts with various cellular proteins, 
most of which are important regulators of the cell cycle, especially the transition from the G1 
to S phase (Table 2).  
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Oncoprotein E7 functions Investigators, year 
Cell immortalization Münger & Phelps, 1993 
Activation of cyclins E and A  Zerfass et al., 1995 
Inhibition of pRb-related pocket proteins  Dyson et al., 1992 
Induction of apoptosis  Puthenveettil et al., 1996 
Inactivation of cyclin-dependent kinase inhibitors  Jones et al., 1997 
Foreign DNA integration Kessis et al., 1996 
Enhancement of DNA mutagenicity  Reznikoff et al., 1996 
Degradation of tyrosine kinase  Oda et al., 1999 
Chromosomal abnormalities  Pett et al., 2004 
E2F-regulated mitotic genes  Thierry et al., 2004 
Table 2. Identified functions of the high-risk HPV oncoprotein E7 
E7 proteins interact with the members of retinoblastoma protein family: pRb, p107 and p130 
(also called “pocket proteins”). Most of the pRb functions are related to the repression of the 
E2F transcription factor. The E7 protein directly binds pRb and targets it for degradation 
through the ubiquitin-dependant pathway (Boyer et al., 1996). Suppression of Rb function 
by E7 results in the activation of E2F, and stimulation of the cell cycle progression (Dyson, 
1998). E7 is also capable of direct interaction with E2F factors and chromatin modifiers such 
as histone deacetylases (HDACs), what additionally affects the expression of S phase genes 
(Hwang et al., 2002; Brehm et al., 1999). E7 protein interacts with cyclin dependent kinases 
(CDK) inhibitors like p21 and p27. While E6 inhibits p21 transcription by inactivating p53, 
E7 inhibits p21 functions by direct binding, thus contributing to sustained activity of CDK, 
such as CDK2. High-risk E7 also increases the expression of CDC25A phosphatase that 
promotes CDK2 activation (Nguyen et al., 2002). All these effects on cell proliferation are 
favourable for HPV life cycle and replication but they also contribute to the uncontrolled 
proliferation of infected cells. Besides disrupting cell cycle control, and allowing the cell 
division in the presence of DNA damage, E6 and E7 are capable of directly inducing DNA 
damage (Moody & Laimins, 2010). Thus, in HPV infected cells a deleterious combination 
could be present: increased DNA damage and impaired response to DNA damage. 
4.4 Telomere maintenance 
While normal cells have finite numbers of doublings before they become senescent 
(“Hayflick limit”), malignant cells acquire limitless replicative potential (Hanahan & 
Weinberg, 2000). The immortality of malignant cells is closely related with telomere 
maintenance (Shay & Bacchetti, 1997; Hanahan & Weinberg, 2000). The majority of 
malignant cells achieve telomere maintenance by up-regulation of telomerase, an enzyme 
that adds hexanucleotide repeats to the 3’ end of DNA strands in the telomere regions. 
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Telomerase is a ribonucleoprotein complex that contains three subunits: a catalytic subunit - 
human telomerase reverse transcriptase (hTERT), a RNA subunit and a protein subunit 
(dyskerin). The expression of hTERT is proportional to telomerase activity in the cells. It has 
been shown that high-risk E6 protein activates transcription of hTERT. E6 in complex with 
E6AP or alone interacts with Myc protein (Veldman et al, 2001; Howie et al., 2009). 
Heterodimer Myc/Max binds to the hTERT promoter and activates its transcription. E6 also 
affects other hTERT activators including Sp1 which binds to the hTERT promoter and 
histone acetyltransferases that increase histone acetylation at the hTERT promoter (Oh et al., 
2001; James et al., 2006). E6 modulates activity of hTERT repressors as well. The HPV 16 
E6/E6AP complex targets hTERT repressor X box-binding protein 1-91 (NFX1-91) for 
polyubiquitination and degradation. E6 affects binding of two other hTERT repressors – 
upstream stimulating factors 1 and 2 (USF1 and USF2). Additionally, E6 directly associates 
with NFX123 that increases hTERT activity by several mechanisms including those on 
transcriptional and post-translational level (Howie et al., 2009). A second mechanism of 
telomere maintenance is recombination-based and is termed alternative lengthening of 
telomeres (ALT) pathway. It has been suggested that the E7 protein affects telomere length 
through the ALT pathway (Spardy et al., 2008). Thus, a cooperative effect between E6 and 
E7 could be achieved regarding telomere maintenance and cell immortalization. The E7 
effect could be important in early cancer development while E6 might play a role in later 
phases of oncogenesis (Moody & Laimins, 2010). This is in accordance with the observation 
that high levels of hTERT expression are found in advanced cervical lesions and invasive 
carcinomas (Zhang et al., 2004). 
4.5 Evading apoptosis 
HPV has developed numerous mechanisms that block host-mediated apoptosis. These 
mechanisms regulate the survival of infected cells thus facilitating the HPV replication cycle. 
Besides blocking p53 function in regulation of apoptosis, high-risk HPV proteins interact 
with both extrinsic and intrinsic apoptotic pathways. The extrinsic pathway is triggered by 
various extracellular signals that activate “death receptors”, members of the tumour 
necrosis factor receptor (TNFR) family. After binding the ligand death receptors form 
trimers and associate with adaptor molecules and initiator caspases. The result is the 
formation of the death inducing signalling complex (DISC). DISC activates caspase 8 which 
cleaves downstream caspases in the apoptotic pathway leading to cell death. High-risk E6 
protein interacts with all components of the DISC complex. E6 binds to the death receptor 
TNFR-1 and blocks its association with adapter molecules (Filippova et al., 2002). 
Furthermore, E6 can accelerate the degradation of some adapter molecules like FADD and 
the initiator caspase-8 (Garnett et al., 2006; Howie et al., 2009). The intrinsic apoptotic 
pathway is activated by various intracellular stressors (DNA damage, oxidative stress and 
others) and includes mitochondrial permeability transition. Then pro-apoptotic signals 
dominate changes in mitochondrial membrane are initiated with formation of pores and 
release of pro-apoptotic proteins. These proteins form an apoptotic signalling complex that 
results in cleavage of downstream caspases (like caspase-3 and caspase-7), leading to 
degradation of cellular components. The E6 protein interacts with intrinsic apoptotic 
pathway signalling by binding Bak, a pro-apoptotic member of Bcl-2 family. E6 binds Bak 
and induces its degradation through the ubiquitin-proteasome pathway (Thomas & Banks, 
1998). The HPV E6 protein is also capable to up regulate the expression of inhibitors of 
apoptosis, such as survivin and the inhibitor of apoptosis protein 2 (IAP2). The studies of 
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HPV E7 in regulation of apoptosis obtained variable results; both, anti-apoptotic and pro-
apoptotic effects have been found (Garnett & Duerksen-Hughes, 2006). HPV oncoproteins 
target a number of factors important for anoikis, a specific type of apoptosis that is induced 
by loss of cell adhesion or inappropriate cell adhesion (Valentijn et al., 2004; Chiarugi & 
Giannoni, 2008). High-risk HPV proteins bind or are associated with changes in expression 
levels of fibronectin, fibulin-1, focal adhesion kinase (FAK) and paxillin (Moody & Laimins, 
2010). These interactions contribute to the capability of HPV infected cells to become 
resistant to anoikis and grow in the absence of anchorage to the extracellular matrix and 
their neighbouring cells. Anchorage independent growth is considered to be a hallmark of 
malignant phenotypes. 
4.6 Escape from immune system surveillance 
The major lines of defence against various pathogens are natural mechanical barriers, innate 
and adoptive immunity. Dendritic cells (DC) are highly specialized antigen presenting cells 
(APC) that play important roles in innate immunity and provide a link between innate and 
adoptive immunity. Toll-like receptors (TLR) located in the membrane or inside the DC 
recognize typical molecular motifs of various pathogens called pathogen-associated 
molecular patterns (PAMPS). Langerhans cells are main DC of the skin and mucosa, being 
important detectors at the site of HPV infection. Activated dendritic cells migrate to 
draining lymph nodes, mature during the migration to highly effective APC and present 
antigens to naïve T lymphocytes, thereby initiating cell-mediated responses. The activated 
effector (cytotoxic) cells target infected cells at the site of infection (Stanley, 2006). Indeed, in 
case of HPV infection in the majority of cases the virus is cleared by cell-mediated 
mechanisms that are clinically associated with complete remission. However, the time for 
clearance ranges from months to years suggesting a delay in immune response. Ten to 
twenty percent of infected persons do not manage to clear the HPV infection and they 
develop persistent infection that is associated with the risk of high-grade cervical lesions 
and invasive carcinoma (zur Hausen, 1996; Stanley, 2010). HPV has developed several 
mechanisms for evading the immune surveillance. The majority of these mechanisms 
contribute to evading of innate immunity that delays the adoptive immune response. Some 
of these mechanisms are related with the characteristics of the viral site of infection and 
some are related to the effects of viral oncoproteins. HPV does not have a lytic phase, and 
thereby does not cause cell injury that would initiate inflammation and/or immune 
response. There is no viraemic stage during HPV infection. Therefore both, locally and 
systemically there is no favourable situation for contact between HPV and the immune 
system. Hasan and colleagues (2007) have shown that high risk E6 and E7 proteins inhibit 
TLR9 transcription leading to impaired activation of the innate immune response. 
Additionally, high-risk proteins interact with interferon regulatory factors (IRF) required for 
the expression of type I interferons: E6 binds IRF-3 while E7 interacts with IRF-1 (Ronco et 
al., 1998; Park et al., 2000). Microarray analysis showed that high-risk proteins down-
regulate the expression of IFN-inducible genes, including signal transducer and activator of 
transcription 1 (STAT1) (Chang & Laimins, 2000). One of the possible mechanisms that 
underlie this phenomenon is direct interaction of HPV 16 E7 with p48-the DNA binding 
component of the interferon-stimulated gene factor 3 (ISGF3) transcription complex, thus 
blocking the translocation of this complex to the nucleus (Barnard & McMillan, 1999). 
Furthermore, HPV proteins interact with the proximal components of interferon-inducible 
pathways. E6 binds and inhibits the function of tyrosin kinase (Tyk2), a component of the 
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JAK-STAT signalling pathway that mediates IFN cellular responses (Li et al., 1999). The 
activity of another interferon-inducible double-stranded RNA protein kinase (PKR) 
pathway is reduced by synergistic action of E6 and E7 (Hebner et al., 2006). Activated PKR-
phosphorylates multiple products leading to various antiviral effects including the 
inhibition of translation. The reduced activity of this pathway results in the maintenance of 
viral protein synthesis. Furthermore, it has been shown that interferon induced growth 
arrest is dependent on p53 acetylation. Post-transcriptional modifications, like acetylation 
affect p53 stability and increases its transcriptional activity. Besides reducing p53 
availability by targeting it for degradation, E6 interacts with p300/CBP that catalyzes 
acetylation of p53. E6 forms a complex with p300/CBP, thus preventing the acetylation of 
p53 (Hebner et al., 2007). This mechanism might contribute to the proliferation of HPV 
infected cells in the presence of interferon (Beglin et al., 2009).  
5. Conclusions 
Genital HPV infection is a most common sexually transmitted infection of viral origin 
among women. The association between persistent HPV infection and malignant 
transformation of the lower female genital tract is well established. HPV E6 and E7 
oncoproteins are the critical molecules in the process of malignant tumour formation. 
Interacting with various cellular proteins, E6 and E7 influence fundamental cellular 
functions like cell cycle regulation, telomere maintenance, susceptibility to apoptosis, 
intercellular adhesion and regulation of immune responses. High-risk E6 and E7 
cooperatively disrupt p53 and pRb functions with profound changes in the cell cycle 
regulation. Uncontrolled cell proliferation leads to increased risk of genetic instability; the 
generator of mutant phenotypes that will contribute to conferring other abnormalities and 
possible advantages for tumour growth. Furthermore, oncoproteins E6 and E7 are capable 
of directly provoking DNA damage. Usually, it takes decades for cancer to arise. Thus, 
cervical carcinogenesis is a multifactorial process involving genetic, environmental, 
hormonal and immunological factors in addition to HPV infection. 
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of DNA will continue for a while to be a leading front of scientific activities.
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